Sole US startup invited to compete in Denmark October 24

SPRINGFIELD, Ill. - Oct. 21, 2013 - PRLog -- Who:  Matt Reavill, owner/inventor of ReavillMED is competing as the only US startup company at the European Venture contest.  Matt Reavill, from Plainfield, Illinois, was extended an invitation to compete over hundreds of applicants.  Reavill designed his device to do evidence based diagnosis of sepsis in hospital Emergency Rooms after losing his father to sepsis.

According to information provided by the National Institutes for Health, the Centers for Disease Control and Prevention, and the Mayo Clinic, severe sepsis strikes approximately 750,000 Americans each year. While early detection and aggressive treatment can improve the chances for survival, sepsis remains a leading cause of death in American hospitals. It is also an extremely costly condition; in 2008, nearly $15 billion was spent on hospitalizations for sepsis.

Between one-third and one-half of all sepsis patients die, and those who survive are more likely to have permanent organ damage, cognitive impairment, and physical disability. According to the New England Journal of Medicine, 10% of all ICU admissions are caused by sepsis, and the CDC notes that patients hospitalized for sepsis are more than eight times more likely to die during their hospitalization than those hospitalized for other diagnoses.

Where:  This year the contest is at Aarhus, Denmark

When:  October 24, 2013

What:  ReavillMED is among 25 competing companies with solutions addressing the unmet needs in medical devices, pharmaceuticals, biotechnologies and e-healthcare.  In 2012, 850+ applicants were reviewed and 130 made it to the finals.  ReavillMED won the Omnicompete Health Pitch Battlefield in 2011, held in London

Contact:  Judith Keller (414) 803-9630, judith.r.keller@gmail.com or info@reavilmed.com (mailto:matt@reavilmed.com)

Links:  www.Reavillmed.com, http://www.healthtechsummit.eu/events/view.aspx?events_pages_id=1783